文献速递脑血管病外科神经重症

内镜手术联合纤溶治疗脑室内出血的疗效:一项随机对照试验

Outcomes of Combined Endoscopic Surgery and Fibrinolytic Treatment Protocol for Intraventricular Hemorrhage: A Randomized Controlled Trial.
PubMed 文献 · World Neurosurg · 2023-01-24

这项随机双盲试验将110例自发性脑出血继发脑室内出血伴梗阻性脑积水患者按1:1分为干预组(内镜手术和/或脑室内纤溶)与对照组(脑室外引流)。干预组180天改良Rankin量表0-3分比例更高(63.6% vs 43.6%,P=0.04),30天死亡率更低(3.6% vs 32.7%,P=0.002),脑室内出血清除率更高且分流转换率更低。结论认为联合内镜手术与脑室内纤溶安全有效。

要点

  • 干预组180天改良Rankin量表0-3分比例为63.6%,对照组为43.6%(P=0.04)。
  • 干预组30天死亡率为3.6%,对照组为32.7%(P=0.002)。
  • 干预组脑室内出血清除率为91%,对照组为69.5%(P<0.01)。

核心结论

  • 联合内镜手术与脑室内纤溶治疗脑室内出血安全有效。
  • 作者认为,积极但安全的脑室内出血清除操作可改善脑室内出血患者的临床结局。

研究设计与样本

  • 随机(1:1)双盲试验,2018年8月至2021年12月开展。
  • 干预组接受内镜手术和/或脑室内纤溶,对照组接受脑室外引流。
  • 纳入自发性脑出血继发原发性或继发性脑室内出血伴梗阻性脑积水并发症的患者。
  • 主要结局为治疗后180天改良Rankin量表评分。
  • 每纳入50例参与者进行中期评估以确保安全性和有效性。

主要发现

  • 纳入110例参与者(每组55例)后,30天死亡率干预组为2例(3.6%),脑室外引流组为13例(32.7%),P=0.002,达到预设的终止边界。
  • 180天改良Rankin量表0-3分干预组为35例(63.6%),对照组为24例(43.6%),P=0.04。
  • 干预组脑室内出血清除率为91%(9.0),对照组为69.5%(38.0),P<0.01。
  • 干预组分流转换率为1例(1.8%),对照组为16例(29.3%),P<0.01。
  • 两组治疗并发症相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraventricular fibrinolysis (IVF) and endoscopic surgery (ES) are the new promising treatment strategies to enhance the rate of hematoma clearance, which might improve functional outcome. This study investigated and compared the outcomes among these interventions. METHODS: A randomized (1:1) double-blinded trial was carried out between August 2018 and December 2021. The intervention and control groups comprised patients receiving IVF and/or ES and external ventricular drainage (EVD), respectively. All participants had experienced primary or secondary intraventricular hemorrhage (IVH) from spontaneous intracerebral hemorrhage with obstructive hydrocephalus complications. The primary outcome was modified Rankin Scale score 180 days post treatment. Interim assessments were planned for every 50 participants enrolled to ensure safety and efficacy. RESULTS: After enrollment of 110 participants (55 participants in each group), there was a difference in 30-day mortality (2 [3.6%] vs. 13 [32.7%] in the EVD group, P = 0.002), reaching the predetermined boundaries for termination of the trial. We demonstrated a better favorable outcome (modified Rankin Scale score 0-3) at 180 days in the intervention group, compared with the control group (35 [63.6%] vs. 24 [43.6%], P = 0.04). Participants in the intervention group experienced a higher IVH removal rate (91% [9.0] vs. 69.5% [38.0], P < 0.01) and had lower shunt conversion (1 [1.8%] vs. 16 [29.3%], P < 0.01). Treatment complications were comparable between the two groups. CONCLUSIONS: This study demonstrated that combined ES and IVF is safe and effective for the treatment of IVH. In addition, it concluded that aggressive but safe procedures used to remove IVH could improve clinical outcome in patients with IVH.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Noiphithak R, Ratanavinitkul W, Yindeedej V, et al. Outcomes of Combined Endoscopic Surgery and Fibrinolytic Treatment Protocol for Intraventricular Hemorrhage: A Randomized Controlled Trial. World Neurosurg. 2023. PMID: 36706982. doi:10.1016/j.wneu.2023.01.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。